Med BioGene Accepts Amended Offer from Precision Therapeutics

Precision Therapeutics made an improved offer, matching the upfront payment offered by Signal Genetics to license the LungExpress Dx technology.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.